Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Genor Doses First Patient in Phase I/II Trial of Bispecific for Lymphoma/Leukemia

publication date: Sep 8, 2022

Beijing Genor Biopharma dosed the first patient in a China Phase I/II clinical trial of GB261, a CD20/CD3 bispecific antibody, that will enroll lymphoma/leukemia patients. GB261 is the first T-Cell Engager with ultra-low affinity to bind CD3 and has Fc-enabled functions (ADCC and CDC). Genor says GB261 inhibits rituximab-resistant cancer cell proliferation in both in vitro assays and in vivo models with a lower level of cytokine release. The trial will enroll patients with relapsed or refractory B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. More details....

Stock Symbol: (HK: 6998)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital